Preventative Health Savings Act (H.R. 2584/S. 1361)
Drug importation, generally
Issues related to the 340B Drug Pricing Program, generally
H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book
Medicare Diabetes Prevention Program
Treat and Reduce Obesity Act (H.R. 1530/S. 595)
Issues related to Medicare Part D, generally; Part D Rebate Rule; 6 Protected Classes
Issues related to International Price Indexing (IPI)/reference pricing in Medicare Part B
CMS coverage of diabetes technologies/services
Medicaid rebate cap, including H.R. 107
Diabetes prevention, generally
Issues related to medication affordability and access, generally
Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
Chronic Disease Management Act (S. 1948/H.R. 3709) and issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases
Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Duration: March 1, 2016
to
December 31, 2019
General Issues: Budget/Appropriations , Pharmacy , Medicare/Medicaid , Health Issues , Taxation/Internal Revenue Code
Spending: about $670,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives
Related Foreign Entities:
Client is wholly-owned subsidiary of Novo Nordisk US (Hellerup, DEN); contribution to lobbying: $0; ownership 100%; Novo Nordisk US is wholly-owned by Novo Nordisk A/S (Hellerup, DEN); contribution to lobbying: $0; ownership 100%; Novo A/S (Owns 26.5% of NN A/S) (Hellerup, DEN); contribution to lobbying: $0; ownership 26%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Steven Irizzary Counsel, House Energy & Commerce Committee; Counsel, Senate Special Committee on Aging; Counsel, Senate HELP; Counsel, Senator Chuck Hagel
Israel "Izzy" Klein Deputy Staff Director, Joint Economic Committee, Chairman Chuck Schumer; Senior Communications Advisor, Representative Ed Markey; Communications Director, Senator Chuck Schumer; Press Secretary and Legislative Assistant, Representative Ed Markey
Steven Irizarry Counsel, House Energy & Commerce Committee; Counsel, Senate Special Committee on Aging; Counsel, Senate HELP; Counsel, Senator Chuck Hagel
Drew Cole Intern for Senator Don Nickels (R-OK)
Lydia Strunk Deputy Floor Director Speaker Ryan (2015-17); Deputy Floor Director Speaker Boehner (2013-15); House Rules Committee 2011-13; House Republican Cloakroom Floor Assistant 2008-2011 (Minority Leader Boehner/Speaker Boehner)
Vincent Roberti n/a
Israel Klein n/a
Vincent Roberti Sr n/a
Vincent Roberti Sr. n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2019
Roberti Global (fka Roberti White, LLC) terminated an engagement in which they represented Novo Nordisk on Jan. 22, 2020.
Original Filing: 301129795.xml
Lobbying Issues
Preventative Health Savings Act (H.R. 2584/S. 1361)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug importation, generally
Issues related to the 340B Drug Pricing Program, generally
H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program
Treat and Reduce Obesity Act (H.R. 1530/S. 595)
Issues related to Medicare Part D, generally; Part D Rebate Rule; 6 Protected Classes
Issues related to International Price Indexing (IPI)/reference pricing in Medicare Part B
CMS coverage of diabetes technologies/services
Medicaid rebate cap, including H.R. 107
Agencies Lobbied
U.S. Senate
Lobbying Issues
Diabetes prevention, generally
Issues related to medication affordability and access, generally
Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
Chronic Disease Management Act (S. 1948/H.R. 3709) and issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2019
Roberti Global (fka Roberti White, LLC) terminated an engagement in which they represented Novo Nordisk on Jan. 18, 2020.
Original Filing: 301121089.xml
Lobbying Issues
Preventative Health Savings Act (H.R. 2584/S. 1361)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug importation, generally
Issues related to the 340B Drug Pricing Program, generally
H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program
Treat and Reduce Obesity Act (H.R. 1530/S. 595)
Issues related to Medicare Part D, generally; Part D Rebate Rule; 6 Protected Classes
Issues related to International Price Indexing (IPI)/reference pricing in Medicare Part B
CMS coverage of diabetes technologies/services
Medicaid rebate cap, including H.R. 107
Agencies Lobbied
U.S. Senate
Lobbying Issues
Diabetes prevention, generally
Issues related to medication affordability and access, generally
Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
Chronic Disease Management Act (S. 1948/H.R. 3709) and issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of Novo Nordisk in Q32019 on Jan. 22, 2020.
Original Filing: 301129794.xml
Lobbying Issues
Preventative Health Savings Act (H.R. 2584/S. 1361)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug importation, generally
Issues related to the 340B Drug Pricing Program, generally
H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program
Treat and Reduce Obesity Act (H.R. 1530/S. 595)
Issues related to Medicare Part D, generally; Part D Rebate Rule; 6 Protected Classes
Issues related to International Price Indexing (IPI)/reference pricing in Medicare Part B
CMS coverage of diabetes technologies/services
Medicaid rebate cap, including H.R. 107
Agencies Lobbied
U.S. Senate
Lobbying Issues
Diabetes prevention, generally
Issues related to medication affordability and access, generally
Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
Chronic Disease Management Act (S. 1948/H.R. 3709) and issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $40,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078259.xml
Lobbying Issues
Preventative Health Savings Act (H.R. 2584/S. 1361)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug importation, generally
Issues related to the 340B Drug Pricing Program, generally
H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program
Treat and Reduce Obesity Act (H.R. 1530/S. 595)
Issues related to Medicare Part D, generally; Part D Rebate Rule; 6 Protected Classes
Issues related to International Price Indexing (IPI)/reference pricing in Medicare Part B
CMS coverage of diabetes technologies/services
Medicaid rebate cap, including H.R. 107
Agencies Lobbied
U.S. Senate
Lobbying Issues
Diabetes prevention, generally
Issues related to medication affordability and access, generally
Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
Chronic Disease Management Act (S. 1948/H.R. 3709) and issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2019
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $40,000. The report was filed on July 22, 2019.
Original Filing: 301056211.xml
Lobbying Issues
Preventative Health Savings Act (H.R. 2584/S. 1361)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug importation, generally
Issues related to the 340B Drug Pricing Program, generally
H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program
Treat and Reduce Obesity Act (H.R. 1530/S. 595)
Issues related to Medicare Part D, generally; Part D Rebate Rule; 6 Protected Classes
Issues related to International Price Indexing (IPI)/reference pricing in Medicare Part B
CMS coverage of diabetes technologies/services
Medicaid rebate cap, including H.R. 107
Agencies Lobbied
U.S. Senate
Lobbying Issues
Diabetes prevention, generally
Issues related to medication affordability and access, generally
Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
Chronic Disease Management Act (S. 1948/H.R. 3709) and issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2019
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $40,000. The report was filed on April 22, 2019.
Original Filing: 301038673.xml
Lobbying Issues
CBO scoring of preventive health services, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the FDA Reauthorization Act (Pub.L. 115-52)
Drug importation, generally
Issues related to the 340B Drug Pricing Program, generally
H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book
Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S.771)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program
Treat and Reduce Obesity Act (H.R. 1530/S. 595)
Issues related to Medicare Part D, generally; Part D Rebate Rule; 6 Protected Classes
Issues related to International Price Indexing (IPI)/reference pricing in Medicare Part B
CMS coverage of diabetes technologies/services
Medicaid rebate cap, including H.R. 107
Agencies Lobbied
U.S. Senate
Lobbying Issues
Diabetes prevention, generally
Issues related to medication affordability and access, generally
Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
Issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $40,000. The report was filed on Jan. 22, 2019.
Original Filing: 301016032.xml
Lobbying Issues
Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act
Drug importation, generally; Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Virtual Medicare Diabetes Prevention Program
Issues related to the 340B Drug Pricing Program, generally; 340B Protecting Access for the Underserved and Safety-Net Entities (340 PAUSE) Act (H.R. 4710)
Issues related to the FDA Reauthorization Act (Pub.L. 115-52)
Improving Access To Affordable Prescription Drugs Act (H.R. 1776/S.771)
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Diabetes Prevention Program and other CDC diabetes prevention activities in Pub.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations).
Issues related to the 340B Drug Pricing Program, generally; 340B Protecting Access for the Underserved and Safety-Net Entities (340 PAUSE) Act (H.R. 4710)
Issues related to the FDA Reauthorization Act (Pub.L. 115-52)
Improving Access To Affordable Prescription Drugs Act (H.R. 1776/S.771)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
Treat and Reduce Obesity Act (H.R. 1953/S. 830)
Medicare Diabetes Prevention Program; diabetes self-management education; Preventing Diabetes in Medicare Act (H.R. 3124/S. 1299)
Issues related to Medicare Part D included in the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625), including coverage gap ("donut hole") access and averting catastrophic coverage Out of Pocket (OOP) "cliff
Agencies Lobbied
U.S. Senate
Lobbying Issues
Chronic Disease Management Act (H.R. 4978/S. 2410)
Diabetes prevention, generally
Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
Growth Awareness Week 2018
Issues related to medication affordability and access, generally
American Health Care Act/Better Care Reconciliation Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $40,000. The report was filed on Oct. 22, 2018.
Original Filing: 300997820.xml
Lobbying Issues
Preventative Health Savings Act (H.R. 2953/S. 216); CBO scoring of preventive health, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Diabetes Prevention Program and other CDC diabetes prevention activities in Pub.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations).
Issues related to the 340B Drug Pricing Program, generally; 340B Protecting Access for the Underserved and Safety-Net Entities (340 PAUSE) Act (H.R. 4710)
Issues related to the FDA Reauthorization Act (Pub.L. 115-52)
Improving Access To Affordable Prescription Drugs Act (H.R. 1776/S.771)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug importation, generally; Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Treat and Reduce Obesity Act (H.R. 1953/S. 830)
Medicare Diabetes Prevention Program; diabetes self-management education
Issues related to Medicare Part D included in the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625), including coverage gap ("donut hole") access and averting catastrophic coverage Out of Pocket (OOP) "cliff
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
Diabetes prevention, generally
Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
World Hemophilia Day
Issues related to medication affordability and access, generally
American Health Care Act/Better Care Reconciliation Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Chronic Disease Management Act (H.R. 4978/S. 2410)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $40,000. The report was filed on July 20, 2018.
Original Filing: 300977130.xml
Lobbying Issues
- Preventative Health Savings Act (H.R. 2953/S. 216); CBO scoring of preventive health, generally
- National Diabetes Prevention Program and other CDC diabetes prevention activities in Pub.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to the 340B Drug Pricing Program, generally; 340B Protecting Access for the Underserved and Safety-Net Entities (340 PAUSE) Act (H.R. 4710)
- Issues related to the FDA Reauthorization Act (Pub.L. 115-52)
- Improving Access To Affordable Prescription Drugs Act (H.R. 1776/S.771)
- Drug importation, generally; Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Treat and Reduce Obesity Act (H.R. 1953/S. 830)
- Medicare Diabetes Prevention Program; diabetes self-management education
- Issues related to Medicare Part D included in the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625)
- Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Diabetes prevention, generally
- Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
- World Hemophilia Day
- Issues related to medication affordability and access, generally
- American Health Care Act/Better Care Reconciliation Act (H.R. 1628)
- Chronic Disease Management Act (H.R. 4978/S. 2410)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $40,000. The report was filed on April 20, 2018.
Original Filing: 300957011.xml
Lobbying Issues
- Preventative Health Savings Act (H.R. 2953/S. 216); CBO scoring of preventive health, generally
- National Diabetes Prevention Program and other CDC diabetes prevention activities in Pub.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to the 340B Drug Pricing Program, generally; 340B Protecting Access for the Underserved and Safety-Net Entities (340 PAUSE) Act (H.R. 4710)
- Issues related to the FDA Reauthorization Act (Pub.L. 115-52)
- Improving Access To Affordable Prescription Drugs Act (H.R. 1776/S.771)
- Drug importation, generally; Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Treat and Reduce Obesity Act (H.R. 1953/S. 830)
- Medicare Diabetes Prevention Program; diabetes self-management education
- Issues related to Medicare Part D included in the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625)
- Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Diabetes prevention, generally
- Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
- World Hemophilia Day
- Issues related to medication affordability and access, generally
- American Health Care Act/Better Care Reconciliation Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $50,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934781.xml
Lobbying Issues
- H.R. 2953/S. 2164 Preventative Health Savings Act (CBO scoring of preventive health)
- National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- H.R. 4710, the 340B Protecting Access for the Underserved and Safety-Net Entities Act (340 PAUSE Act)and other issues related to 340B program
- Issues related to P.L. 115-52 (H.R. 2430/S. 934)
- H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act
- H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
- H.R. 1953/S. 830 Treat and Reduce Obesity Act
- Medicare Diabetes Prevention Program; diabetes self-management education
- Issues related to Medicare Part D
- H.R. 849/S. 260 Protecting Seniors Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- General diabetes prevention
- P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act
- World Hemophilia Day
- H. Res. 142 and S. Res. 63/S. Res. 325 (A resolution) expressing support for designation of the week of October 29 through November 4, 2017, as "National Obesity Care Week"
- H.R. 1628 American Health Care Act (AHCA) and Better Care Reconciliation Act of 2017
Agencies Lobbied
U.S. Senate
Lobbying Issues
- P.L. 115-97 (H.R. 1 Tax Cuts and Jobs Act) including Orphan Drug Tax Credit (ODTC)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300914715.xml
Lobbying Issues
- Preventive Health Savings Act (H.R. 2953)
- National Diabetes Prevention Program in FY 2018 Labor, HHS & Education Appropriations
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- FDA Reauthorization Act (H.R. 2430/S. 934)
- Improving Access to Affordable Prescription Drug Act (H.R. 1776/S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Treat and Reduce Obesity Act (H.R. 1953/S. 830)
- Issues related to the Medicare Diabetes Prevention Program and self-management education
- Issues related to Medicare Part D
- IPAB repeal, including the Protecting Medicare from Executive Action Act (S. 251) and Protecting Seniors' Access to Medicare Act (H.R. 849/S. 260)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to diabetes screening and prevention
- Clinical Care Commission Act (H.R. 309/S. 920)
- World Hemophilia Day
- National Obesity Care Week (H. Res. 142/S. Res. 63)
- American Health Care Act (H.R. 1628) and Better Care Reconciliation Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Corporate tax reform, including border adjustment tax and interest deductibility
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300894473.xml
Lobbying Issues
- Preventive Health Savings Act (H.R. 2953)
- National Diabetes Prevention Program in FY 2018 Labor, HHS & Education Appropriations
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- FDA Reauthorization Act (H.R. 2430/S. 934)
- Improving Access to Affordable Prescription Drug Act (H.R. 1776/S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Treat and Reduce Obesity Act (H.R. 1953/S. 830)
- Issues related to the Medicare Diabetes Prevention Program and self-management education
- Issues related to Medicare Part D
- IPAB repeal, including the Protecting Medicare from Executive Action Act (S. 251) and Protecting Seniors' Access to Medicare Act (H.R.849/S. 260)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to diabetes screening and prevention
- Clinical Care Commission Act (H.R. 309/S. 920)
- World Hemophilia Day
- American Health Care Act (H.R. 1628) and Better Care Reconciliation Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Corporate tax reform, including border adjustment tax and interest deductibility
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $50,000. The report was filed on April 20, 2017.
Original Filing: 300876784.xml
Lobbying Issues
- Budget matters relating to the National Diabetes Prevention Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Treat and Reduce Obesity Act (H.R. 1953/S. 830)
- Issues related to the Medicare Diabetes Prevention Program and self-management education
- Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to diabetes screening and prevention
- Clinical Care Commission Act (H.R. 309)
- World Hemophilia Day
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drugs Act (S. 771)
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Corporate tax reform, including border adjustment tax and interest deductibility
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $50,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856362.xml
Lobbying Issues
- Budget matters relating to the National Diabetes Prevention Program, as well as the Department of Health and Human Services (HHS), Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), and National Institutes of Health (NIH), generally
-H.R. 3660, S. 3126 - To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- 21st Century Cures Act (H.R. 6)
- Innovation for Healthier Americans (Senate)
- Issues relating to biosimilars and the Biologics Price Competition and Innovation Act (P.L. 111-148)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Treat and Reduce Obesity Act (H.R. 2404/S. 1509)
- Issues related to Medicare diabetes screening, generally, Medicare Part D, Special Dabetes Program, obesity, and medical nutrition therapy services
- IPAB, generally, including the Protecting Seniors' Access to Medicare Act (H.R. 1190/S. 141)
- Access to Quality Diabetes Education Act (H.R. 1726)
- CMMI Part B Drug Price Demonstration Program
- Medicare Diabetes Prevention Act (H.R. 2102 and S. 1131)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA), Generic Drug User Fee Act (GDUFA), and Biosimilars User Fee Act (BsUFA)
- National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586)
- Congressional recognition of World Hemophilia Day
- Issues involving the implementation of the Food and Drug Safety and Innovation Act (FDASIA), including the Biologics Price Competition and Innovation Act (BPCIA)
- Issues related to diabetes generally, and specifically diabetes screening, medical education, and AHRQ and USPSTF diabetes screening standards
- National Diabetes Prevention Program
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $30,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837940.xml
Lobbying Issues
- Budget matters relating to the National Diabetes Prevention Program, as well as the Department of Health and Human Services (HHS), Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), and National Institutes of Health (NIH), generally
-H.R. 3660, S. 3126 - To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- 21st Century Cures Act (H.R. 6)
- Innovation for Healthier Americans (Senate)
- Issues relating to biosimilars and the Biologics Price Competition and Innovation Act (P.L. 111-148)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Treat and Reduce Obesity Act (H.R. 2404/S. 1509)
- Issues related to Medicare diabetes screening, generally, Medicare Part D, Special Dabetes Program, obesity, and medical nutrition therapy services.
- IPAB, generally, including the Protecting Seniors' Access to Medicare Act (H.R. 1190/S. 141).
- Access to Quality Diabetes Education Act (H.R. 1726).
- CMMI Part B Drug Price Demonstration Program
- Medicare Diabetes Prevention Act (H.R. 2102 and S. 1131)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA), Generic Drug User Fee Act (GDUFA), and Biosimilars User Fee Act (BsUFA)
- National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586)
- Congressional recognition of World Hemophilia Day
- Issues involving the implementation of the Food and Drug Safety and Innovation Act (FDASIA), including the Biologics Price Competition and Innovation Act (BPCIA)
- Issues related to diabetes generally, and specifically diabetes screening, medical education, and AHRQ and USPSTF diabetes screening standards
- National Diabetes Prevention Program
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $30,000. The report was filed on July 20, 2016.
Original Filing: 300820558.xml
Lobbying Issues
- Budget matters relating to the National Diabetes Prevention Program, as well as the Department of Health and Human Services (HHS), Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), and National Institutes of Health (NIH), generally
- H.R. 3660, S. 3126 - To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- 21st Century Cures Act (H.R. 6)
- Innovation for Healthier Americans (Senate)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Treat and Reduce Obesity Act (H.R. 2404/S. 1509)
- Medicare Diabetes Prevention Act (H.R. 2102 and S. 1131)
- CMMI Part B Drug Payment Demonstration
- Medicare Diabetes Prevention Act (H.R. 2102 and S. 1131)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA), Generic Drug User Fee Act (GDUFA), and Biosimilars User Fee Act (BsUFA)
- Issues involving the implementation of the Food and Drug Safety and Innovation Act (FDASIA), including the Biologics Price Competition and Innovation Act (BPCIA)
- Issues related to diabetes generally, and specifically diabetes screening, medical education, and AHRQ and USPSTF diabetes screening standards;
- National Diabetes Prevention Program
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Novo Nordisk , earning $30,000. The report was filed on April 20, 2016.
Original Filing: 300803069.xml
Lobbying Issues
- Budget matters relating to the National Diabetes Prevention Program, as well as the Department of Health and Human Services (HHS), Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), and National Institutes of Health (NIH), generally
- H.R. 3660 - To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- 21st Century Cures Act (H.R. 6)
- Innovation for Healthier Americans (Senate)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Treat and Reduce Obesity Act (H.R. 2404/S. 1509)
- Medicare Diabetes Prevention Act (H.R. 2102 and S. 1131)
- Issues related to Medicare diabetes screening, generally, Medicare Part D, Special Diabetes Program, obesity, and medical nutrition therapy services
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA), Generic Drug User Fee Act (GDUFA), and Biosimilars User Fee Act (BsUFA)
- Issues involving the implementation of the Food and Drug Safety and Innovation Act (FDASIA), including the Biologics Price Competition and Innovation Act (BPCIA)
- Issues related to diabetes generally, and specifically diabetes screening, medical education, and AHRQ and USPSTF diabetes screening standards;
- National Diabetes Prevention Program
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
Roberti Global (fka Roberti White, LLC) filed a lobbying registration on April 4, 2016 to represent Novo Nordisk, effective March 1, 2016.
Original Filing: 300788412.xml
Issue(s) they said they’d lobby about: BUD: Budget matters relating to the National Diabetes Prevention Program, HHS, CMS, FDA, and NIH, generally; H.R. 3660 - To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings PHR: Issues relating to the 340B Drug Pricing Program; 21st Century Cures Act (H.R. 6); Innovation for Healthier Americans (Senate) MMM: Treat and Reduce Obesity Act (H.R. 2404/S. 1509); Medicare Diabetes Prevention Act (H.R. 2102/S. 1131); Medicare reimbursement issues, generally HCR: Issues involving the FFDCA, including the various user fee acts; FDASIA; and the BPCIA .
1st Quarter, 2016
Roberti Global (fka Roberti White, LLC) filed a lobbying registration on March 29, 2016 to represent Novo Nordisk, effective March 1, 2016.
Original Filing: 300787951.xml
Issue(s) they said they’d lobby about: BUD: Budget matters relating to the National Diabetes Prevention Program, HHS, CMS, FDA, and NIH, generally; H.R. 3660 - To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings
PHR: Issues relating to the 340B Drug Pricing Program; 21st Century Cures Act (H.R. 6); Innovation for Healthier Americans (Senate)
MMM: Treat and Reduce Obesity Act (H.R. 2404/S. 1509); Medicare Diabetes Prevention Act (H.R. 2102/S. 1131); Medicare reimbursement issues, generally
HCR: Issues involving the FFDCA, including the various user fee acts; FDASIA; and the BPCIA .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...